CME Group filed a petition with the SEC on July 29, 2026, asking the agency to reconsider its May approval of Nasdaq PHLX's Bitcoin index options, known as QBTC. The SEC's approval was automatically stayed after CME challenged it on June 11, and no deadline has been set for a decision.
The core of CME's argument
CME contends that QBTC is a commodity-option swap under the Commodity Exchange Act, placing it under the exclusive jurisdiction of the CFTC. The exchange says the SEC overstepped by using Exchange Act Section 3B and Dodd-Frank Section 717 to classify the product as a security. QBTC is cash-settled, with each contract representing roughly one Bitcoin, priced using the CME CF Bitcoin Real Time Index and settled on the New York variant of the CME CF Bitcoin Reference Rate.
CME's own cryptocurrency derivatives are booming. The exchange averaged 407,200 contracts per day in 2026, up 46% year-over-year, with average daily open interest of 335,400 contracts. CME already offers Bitcoin options tied to the BRRNY benchmark, certified in October 2025, representing 0.01 Bitcoin per contract and traded under CFTC rules. The exchange warns that the SEC's approval of QBTC could create a competitive injury and raise compliance costs for CME's exchanges and clearing operations. It has not quantified potential losses.
QBTC still needs more approvals
Even if the SEC's approval stands, QBTC cannot trade yet. It still requires relief from the CFTC and documentation approval from the OCC. The product would be cleared by the Options Clearing Corporation in its SEC-regulated capacity, not under the full derivatives clearing framework that CME follows. That distinction is central to CME's argument about regulatory turf.
What happens next
Public comments on the matter are due by August 24, 2026. The SEC has not indicated when it will rule on CME's petition. Until then, the stay remains in place, and QBTC cannot launch.
